JPRN-jRCT2031210455已完成1 期
Single Ascending Dose Study of M529101 in Healthy male Subjects
ishiura Tomoyuki0 个研究点目标入组 32 人开始时间: 2021年11月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 35age old（—）
- 性别
- Male
入选标准
- •(1)Healthy Non-smoking men who are 20 to 34 years of age at the time of informed consent.
- •(2)BMI of 18.5 to 24.9 kg/m2
排除标准
- •(1)Individuals with a history of hepatic, renal, cardiac and other cardiovascular, gastrointestinal, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
- •(2)Individuals with a dental, oral or pharyngeal mucosa disease (including wounds)
- •(3)Individuals with subjective symptom of dysgeusia
研究者
相似试验
已完成
不适用
A phase 1 single ascending dose study in healthy subjects to evaluate safety, tolerability, and pharmacokinetics of XVR011COVID-1910047438NL-OMON49939ExeVir Bio BV30
尚未招募
1 期
Single-dose study of M707102 in healthy subjectsActinic keratosisJPRN-jRCT2071230090ishiura Tomoyuki16
未知
1 期
A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell MalignanciesBlood Cancer, Advanced B Cell MalignanciesJPRN-jRCT2080221827AstraZeneca
未知
1 期
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid TumorsSolid TumorJPRN-jRCT2080221965Eli Lilly Japan K.K.
撤回
1 期
A Phase 1 Single Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EARLI-001ACTRN12622001571763Earli Pty. Ltd.10